A small fraction of patients with asthma have severe, persistent disease that is often refractory to standard therapy. To meet this need, a growing emphasis has been placed on the development of alternative, novel therapies and the ability to characterize those patients who are most likely to benefit from these therapies. The eosinophil has been identified as a primary mediator in airway inflammation and as a potential pharmacological target. This narrative review outlines the need for more phenotype-directed therapies in severe asthma, and discusses the supporting evidence for monoclonal antibodies directed against key pro-eosinophilic T-helper 2 (Th2) inflammatory cytokines as additive agents in the treatment of severe asthma with an eosinophilic phenotype.
INTRODUCTION
Asthma affects 25.7 million people worldwide, and is associated with a significant healthcare and economic burden to patients and society [1] . Three to ten percent of adults diagnosed with asthma are believed to suffer from severe, refractory disease [2, 3] . A single exacerbation requiring urgent intervention can increase the annual treatment costs by as much as threefold [4] , and recurrent exacerbations have been shown to result in a progressive loss of lung function in some patients [5] . Up to 30% of adults with severe asthma will require oral corticosteroids in addition to inhaled corticosteroids to maintain control [6] [7] [8] .
There is a need to identify those patients who are most at risk for exacerbations and to characterize the potential treatment options that might reduce these risks [9] . It has been suggested that within this group of patients, detailed phenotyping or characterizing based on readily observable traits [10] using clinical symptoms, markers of inflammation, and lung function might be useful [3, 9, 11] . Although there is no widely agreed upon phenotypic classification scheme, most proposed groupings include an early-atopic or allergic group, a delayed-onset group (often involving obese patients with a female predominance), and a late-onset, eosinophilic predominant group [3, [10] [11] [12] , as shown in Table 1 . However, in asthma, each phenotype does not necessarily yield a distinct endotype or subgroup defined by pathogenetic mechanisms of disease at a more cellular level [10] . This consensus has shifted the current research focus towards differentiating the pathobiologic mechanisms of each group so that targeted therapies can be developed.
Recurrent exacerbations are a major contributor to asthma-related morbidity in Table 1 Phenotypes of asthma [8, 12, 13, [9, 13] . Although inhaled corticosteroids are effective at reducing airway eosinophilia, up to 50% of patients with severe asthma will have persistent eosinophilia despite treatment [14, 15] , suggesting that selective targeting of airway eosinophilia may have benefit. The purpose of this narrative review is to illustrate both the importance of eosinophilic inflammation in the airway as a distinct subtype of severe asthma, and to review the biologic therapies that are under investigation to specifically treat this patient population. This article is based on previously conducted studies (see Table 2 ), and does not involve any new studies of human or animal subjects performed by any of the authors.
ROLE OF EOSINOPHILS
Eosinophils have been shown to promote airway inflammation and remodeling in asthma [16] , and elevated peripheral blood eosinophil counts have been identified as an independent risk factor for asthma exacerbations [17] [18] [19] [20] . Additionally, a reduction in sputum eosinophil count in those patients with moderate to severe asthma has been shown to reduce exacerbations [21] [22] [23] and hospital admissions [21] . ). However, there was no effect on asthma symptoms or forced expiratory volume in one second (FEV 1 ), suggesting that these markers of disease may be improved through other mechanisms. The only serious adverse events reported were hospitalizations for severe asthma (10% mepolizumab vs. 34% placebo).
A follow-up report by the same authors 12 months after trial completion included the majority (56 of 61) of subjects included in the original study [40] . After cessation of mepolizumab, participants experienced significant increases in peripheral blood and sputum eosinophil counts as soon as three months after trial completion, followed by an increase in exacerbation frequency and worsening asthma control as noted by the Juniper Asthma Control Questionnaire (JACQ).
The increase in both peripheral blood and sputum eosinophils preceding the increase in rate of The authors speculate that the higher eosinophil threshold of C400 cells/lL for inclusion in these studies may more accurately represent airway eosinophilia [47] , and may ultimately better predict which patients will respond to inhibition of IL-5. With the exception of two patients who suffered from anaphylaxis that was believed to be related to the study medication, adverse events were similar in the two groups [48] .
A confirmatory trial comparing two doses of reslizumab [49] controlled asthma unselected for eosinophilia [50] . When compared to placebo, there was no difference in FEV 1 , ACQ scores, or rescue inhaler use between groups. The study was not powered for detailed subgroup analyses, but in those participants with a peripheral blood eosinophil count of C400 cells/lL, there was a significant improvement in FEV 1 (270 mL) compared to placebo, supporting a blood eosinophil threshold of C400 cells/lL for clinical use.
Based on the previous body of work [46, [48] [49] [50] , reslizumab was approved for use in the US on March 23, 2016 by the FDA [51] and the EU on June 23, 2016 by the EMA [52] for add-on maintenance therapy for severe asthma in adults aged 18 years or older with an eosinophilic phenotype. The recommended dose is 3 mg/kg every four weeks administered by intravenous infusion over 20-50 min [53] . Anaphylaxis was reported in 0.3% of patients included in all clinical trials (0% in placebo). Other adverse effects include oropharyngeal pain (2.6% vs. 2.2% placebo) and creatine phosphokinase (CPK) elevation (14% vs. 9% placebo) [53] .
BENRALIZUMAB
Rather than directly binding and inhibiting IL-5, benralizumab is an investigational humanized monoclonal antibody that is directed at a subunit of the IL-5 receptor (IL-5R) located on eosinophils and basophils that induces apoptosis [54] . In a small phase-one trial, intravenous and subcutaneous benralizumab was shown to effectively decrease eosinophil counts in both peripheral blood and sputum, with a trend toward a reduction in peripheral blood basophil counts compared to placebo [55] . In a phase two, randomized, double-blind, placebo-controlled parallel group study, patients with physician-diagnosed asthma and at least one exacerbation requiring urgent care in the preceding 12 months who presented to the emergency department with an acute asthma exacerbation were randomized to either a single dose of benralizumab (0.3 or 1.0 mg/kg) or placebo in addition to usual care administered at the time of presentation, and were followed over a 12-week period [56] .
Patients were enrolled regardless of peripheral blood eosinophil levels. There was no difference between groups in number of exacerbations at four, 12, or 24 weeks, FEV 1 , ACQ, or AQLQ scores. However, pooled analysis found that benralizumab significantly decreased the rate of exacerbations when compared to placebo (p = 0.01).
Interestingly, the effect of benralizumab was not related to blood eosinophil count in this study.
A second larger randomized, controlled, dose-ranging trial enrolled adults with uncontrolled moderate-to-severe asthma and a history of recurrent exacerbations to receive benralizumab over one year at varying doses [57] . Patients were classified as either eosinophilic or non-eosinophilic based on an elevated FeNo ([50 ppb) in combination with a mathematical algorithm to predict sputum eosinophils. A significant reduction in annual exacerbation rate was found in those subjects with an eosinophilic subtype who received 100 mg benralizumab versus those who received placebo, although, due to the nature and goals of the study, the authors accepted p\0.169 as significant rather than the traditional 0.05. Additionally, there were significant improvements in FEV 1 and ACQ-6 scores in all subjects, regardless of phenotype, who received benralizumab compared to those who did not. The activity in the non-eosinophilic subtype suggests that benralizumab may be active towards other IL-5R-expressing cells that contribute to inflammation [57] . 
DUPILUMAB

LEBRIKIZUMAB
Interleukin-13 (IL-13) is a pro-inflammatory
Th2 cytokine secreted by activated T-cells, eosinophils, natural killer cells, mast cells, and basophils that acts as a potent stimulator of mucus production, airway fibrotic changes, and airway eosinophilia [62] . Serum levels are elevated in asthma, and this is thought to be a mechanism of steroid resistance [63] . One of the mechanisms by which IL-13 induces airway fibrosis and remodeling is by upregulating the secretion of periostin [64] , which has been linked as a systemic biomarker specific for airway eosinophilia [65] . Lebrikizumab is a humanized monoclonal antibody that binds to IL-13, which is under investigation for the treatment of uncontrolled asthma [66, 67] .
Early studies indicate that lebrikizumab may improve lung function (percent improvement in baseline FEV 1 compared to placebo ranged from 8.2% to 10.7% in three phase-two trials [66, 67] , although this improvement seems to be limited to those patients with high baseline levels of systemic periostin (C50 ng/mL). In secondary analysis, lebrikizumab was also shown to decrease FeNo, another marker of eosinophilic airway inflammation [68] .
CONCLUSION
Asthma is a complex chronic inflammatory condition where patients with severe eosinophilic airway disease pose a particular challenge for clinicians. As new biologic therapies targeted at specific subtypes of asthma become available, it will be increasingly important to be able to readily identify those subgroups of patients who will be the most likely to respond. Our concept of asthma phenotyping has evolved from emphasizing broad clinical classifications to much more specific biologic characteristics that can more clearly link the underlying pathology to the phenotype.
The place of these new biologic agents in our armamentarium of options for patients with uncontrolled disease is still being defined, but the decision to begin such therapies should carefully weigh the cost of the agent, its safety profile, and the target population. Standard asthma therapies should be optimized according to national guidelines [69, 70] , with attention paid to adherence and control of comorbid conditions before the addition of biologics. For currently approved therapies [44, 53] , we recommend consideration prior to the initiation of chronic systemic steroids to reduce the risk of exacerbations, or to use them in add-on therapies as potential steroid-sparing agents. While strategies for long-term monitoring of these agents have not been defined, we recommend a year-long trial for those patients who tolerate the medications, with the monitoring of frequency of exacerbations and healthcare utilization, the assessment of asthma control with standardized questionnaires, and the ability to wean systemic corticosteroids as primary goals.
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